Status:
COMPLETED
Montelukast for Early Life Wheezing
Lead Sponsor:
University of Massachusetts, Worcester
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Lung Diseases
Asthma
Eligibility:
All Genders
3-3 years
Phase:
PHASE2
PHASE3
Brief Summary
This study will determine the effects of montelukast on the duration of wheezing in children 12 months to 3 years of age who visit a physician for care of a wheezing illness. Only patients from the An...
Detailed Description
BACKGROUND: Asthma has a large impact on the children of our society. It is among the most common chronic diseases of childhood and is the leading cause of absenteeism from school. It is unknown as t...
Eligibility Criteria
Inclusion
- Physician-diagnosed wheezing illness
Exclusion
- Asthma
- Prematurity
- Known intolerance to montelukast
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2016
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT00115297
Start Date
September 1 2004
End Date
October 1 2016
Last Update
March 14 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Massachusetts/UMass Memorial
Worcester, Massachusetts, United States, 01650